Chime Biologics has partnered with Polpharma Biologics to advance the development and manufacture of a biosimilar product for the global market.
Under the agreement, Chime will support Polpharma Biologics, including the entire biosimilar development process from the investigational new drug (IND) stage to commercial supply.
The collaboration aims to leverage Chime’s extensive experience in biosimilar production.
Chime Biologics is a contract development and manufacturing organisation (CDMO) well-equipped to meet the increasing demand for biosimilars worldwide.
The company offers end-to-end solutions, including cell line development, process and analytical development, manufacturing capabilities, and regulatory support.
The partnership aligns with Chime’s goal of delivering high-quality, cost-effective biologics and expanding its presence in Europe, focusing on biosimilar development.
Chime Biologics president Jimmy Wei said: “We are thrilled to contribute to Polpharma Biologics’ growth as we provide all-in-one solutions to accelerate biosimilar development and reduce the time-to-market.
“This collaboration reinforces our strategy of delivering high-quality, affordable biologics to patients worldwide.”
Polpharma Biologics is a Poland-based biotechnology company specialising in biosimilars and has a robust pipeline of early-stage and late-stage biosimilars.
The company has two biosimilar products approved by the US Food and Drug Administration (FDA) and EMA, namely ranibizumab and natalizumab.
Polpharma operates internationally with integrated functions in the European Union (EU).
The company develops biosimilar therapies for a range of conditions and focuses on transitioning products from cell line development to commercial-scale production.
Polpharma Biologics supervisory board member Konstantin Matentzoglu said: “Partnering with Chime Biologics supports our strategic vision to swiftly bring affordable biosimilars developed in Europe to global markets.
“By working with Chime Biologics, we can accelerate patient access to biosimilar therapies. This partnership further strengthens Polpharma Biologics’ global position as a leading biosimilars developer, while leveraging Asian partners with optimised cost-benefit ratio.”
